Fundraising Fox
/Companies
Sign in

Amber Therapeutics

Founded 2021 · 63 employees on LinkedIn · 5 known investors

Find your way into Amber Therapeutics

Sign up to see every warm intro you have to Amber Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Amber Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.

Medical Devices

Investors · 5

Intuitive Ventureslisted by Intuitive VenturesSunnyvale

How we know: the VCSheet dataset · Not right? Tell us

Lightstone Ventureslisted by Lightstone VenturesPortola Valley

How we know: Lightstone Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Oxford Science Enterpriseslisted by Oxford Science EnterprisesOxford · $63.5K – $31.8M

How we know: Oxford Science Enterprises's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

$100M disclosed across 1 of 2 rounds · 2024–2026

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

AmberAmber Bio is a biotechnology company developing a novel RNA writing platform capable of multi-kilobase gene edits that can treat multiple mutations across patients with a single product.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
LatticeWorkLatticeWork develops privacy-focused cloud infrastructure and consumer products that enable people to protect their digital data without relying on centralized cloud services. The company builds personal hybrid cloud solutions for individuals concerned about data privacy.

Companies working in the same space as Amber Therapeutics.

In the news

Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the USglobenewswire.com · Feb 2026Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval - BioSpacebiospace.com · Jun 2024Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approvalglobenewswire.com · Jun 2024

Frequently asked questions

What does Amber Therapeutics do?
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Who are Amber Therapeutics's investors?
Amber Therapeutics's investors include F-Prime Capital, Intuitive Ventures, Lightstone Ventures, New Enterprise Associates (NEA), Oxford Science Enterprises.
How much funding has Amber Therapeutics raised?
Amber Therapeutics has disclosed $100M raised across 1 of its 2 known rounds.